Key facts
- This page summarizes Marc L. Panoff's Form 4 filing for LB PHARMACEUTICALS INC.
- 11 reported transactions and 11 derivative rows are listed below.
- Accepted by SEC: 29 Sep 2025, 20:16.
Marc L. Panoff - 10 Sep 2025 Form 4 Insider Report for LB PHARMACEUTICALS INC
- Reporting relationship
- Senior Vice President, Finance
- Issuer ticker
- LBRX on Nasdaq
- Reported as of
- 10 Sep 2025
- Net transaction value
- $0
- Reporting owner signature
- /s/ Marc Panoff
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Marc L. Panoff filed Form 4 for LB PHARMACEUTICALS INC on 29 Sep 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001304340
Primary reporting owner
PANOFF MARC L
- Relationship
- Senior Vice President, Finance
- Address
- C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK
- Signature
- /s/ Marc Panoff
- Signature date
- 12 Sep 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -3,944
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,944
- Exercise price
- $64.15
- Footnotes
- F1, F2
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +3,944
- Change %
- Price
- Shares after
- 3,944
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,944
- Exercise price
- $15.00
- Footnotes
- F1, F2
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -896
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 896
- Exercise price
- $69.72
- Footnotes
- F1, F2
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +896
- Change %
- Price
- Shares after
- 896
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 896
- Exercise price
- $15.00
- Footnotes
- F1, F2
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -1,255
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,255
- Exercise price
- $69.72
- Footnotes
- F1, F2
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +1,255
- Change %
- Price
- Shares after
- 1,255
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,255
- Exercise price
- $15.00
- Footnotes
- F1, F2
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -14,343
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,343
- Exercise price
- $41.84
- Footnotes
- F2, F3
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +14,343
- Change %
- Price
- Shares after
- 14,343
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,343
- Exercise price
- $15.00
- Footnotes
- F2, F3
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -7,171
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,171
- Exercise price
- $41.84
- Footnotes
- F2, F4
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +7,171
- Change %
- Price
- Shares after
- 7,171
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,171
- Exercise price
- $15.00
- Footnotes
- F2, F4
LBRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +90,525
- Change %
- Price
- $0.000000
- Shares after
- 90,525
- Date
- 10 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 90,525
- Exercise price
- $15.00
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Immediately exercisable.
Footnote F2
The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
Footnote F3
One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Footnote F4
One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Footnote F5
One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.